Results 81 to 90 of about 30,028 (235)

Mecanismos moleculares que relacionam a hipercolesterolemia familiar à doença de Alzheimer [PDF]

, 2015
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Bioquímica, Florianópolis, 2015.A hipercolesterolemia familiar é uma doença do metabolismo das lipoproteínas causada por anormalidades ...
Oliveira, Jade de
core  

Statins for children with familial hypercholesterolemia [PDF]

, 2017
Background: Familial hypercholesterolemia is one of the most common inherited metabolic diseases and is an autosomal dominant disorder meaning heterozygotes, or carriers, are affected. Those who are homozygous have severe disease.
Vuorio, A., Humphries, S.E., Kovanen, P.T., Drogari, E., Tonstad, S., Wiegman, A., Kuoppala, J., Ramaswami, U.   +7 more
core   +2 more sources

Quantification of low density lipoprotein binding and cholesterol accumulation by single human fibroblasts using fluorescence microscopy.

Journal of Lipid Research, 1980
Using fluorescence microscopy, we have quantified low density lipoprotein (LDL) binding by indirect immunofluorescence and cellular cholesterol with the fluorescent sterol-binding polyene, filipin, in individual cultured human fibroblasts from normal ...
H S Kruth, M Vaughan
doaj   +1 more source

[Heterozygous familial hypercholesterolemia].

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015
Heterozygous familial hypercholesterolemia (HeFH) is an autosomal co-dominant inherited disease associated with increased risk of early cardiovascular disease. Plasma low-density lipoprotein concentrations of the affected individuals are 2 to 3 times higher than the normal population.
Özgür Ulaş, Özcan, Sadi, Güleç
openaire   +1 more source

Genomic and Sex Contributions to Interindividual Variability in Pitavastatin Bioavailability

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Aim This study investigates pharmacogenetic determinants of pitavastatin disposition using a candidate‐gene approach. Methods In 48 healthy volunteers, 138 variants across 40 genes involved in drug metabolism and transport were analysed to assess their relationship with pitavastatin pharmacokinetics, alongside the influence of sex and ...
Eva González‐Iglesias, Sofía Moreno‐Pérez de Villar, Dolores Ochoa, Manuel Román, Jesús Novalbos, Samuel Martín‐Vilchez, Alejandro de Miguel, Francisco Abad‐Santos   +7 more
wiley   +1 more source

Molecular basis of familial hypercholesterolemia

, 2017
Purpose of review To provide an overview about the molecular basis of familial hypercholesterolemia. Recent findings Familial hypercholesterolemia is a common hereditary cause of premature coronary heart disease. It has been estimated that 1 in every 250
Hovingh, Gerard K., Gerard K. Hovingh, Caroline S. Bruikman, Bruikman, Caroline S., John J.P. Kastelein, Kastelein, John J. P.   +5 more
core   +1 more source

Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia [PDF]

, 1999
Background The aortic valve dysfunction of patients with homozygous familial hypercholesterolemia (FH) suggests that hypercholesterolemia affects not only coronary arteries, but also the aortic valve.
Yutani, Chikao, Miyatake, Kunio, Tsushima, Motoo, Yamamura, Taku, Beppu, Shintarou, Yamamoto, Akira, Kawaguchi, Akito   +6 more
core   +1 more source

PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report

Frontiers in Cardiovascular Medicine
BackgroundApproximately 3.8 million patients in China suffer from familial hypercholesterolemia (FH). Statins and PCSK9 inhibitors are recommended by guidelines as therapeutic agents.
Yuan Li, Huiyan Jiang, Yajuan Xiong, Simin Yan, Xin Chen   +4 more
doaj   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

The treatment of heterozygous familial hypercholesterolemia — a local perspective

Endokrynologia Polska, 2021
none.
openaire   +3 more sources